Document is current
Any future updates will be listed below
-
Authors
Efficace, Fabio https://orcid.org/0000-0002-5065-5166
Mahon, Francois-Xavier
Richter, Johan https://orcid.org/0000-0002-0374-6823
Piciocchi, Alfonso https://orcid.org/0000-0001-8648-885X
Cipriani, Marta https://orcid.org/0000-0001-6159-8059
Nicolini, Franck E.
Mayer, Jiri
Zackova, Daniela https://orcid.org/0000-0001-9802-8148
Janssen, Jeroen J. W. M. https://orcid.org/0000-0001-9567-1955
Panayiotidis, Panayiotis
Vestergaard, Hanne
Koskenvesa, Perttu
Almeida, Antonio https://orcid.org/0000-0003-4361-0928
Hjorth-Hansen, Henrik https://orcid.org/0000-0002-2670-5696
Martinez-Lopez, Joaquin
Olsson-Strömberg, Ulla
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Berger, Marc G.
Etienne, Gabriel
Klamova, Hana https://orcid.org/0009-0000-5020-7040
Faber, Edgar
Rousselot, Philippe
Pfirrmann, Markus https://orcid.org/0000-0002-8948-0690
Saussele, Susanne https://orcid.org/0000-0003-0357-5785
- License Information
-
More Information
Article History
Received: 23 April 2024
Revised: 26 June 2024
Accepted: 3 July 2024
First Online: 10 July 2024
Competing interests
: Fabio Efficace had a consultancy or advisory role for AbbVie, Incyte, Novartis and JAZZ Pharmaceuticals, outside the submitted work. Franck E. Nicolini: Consultant for Novartis, Sun Pharma Ltd, board entity for Novartis, Incyte Biosciences, Pfizer, institutional grants from Novartis, Incyte Biosciences Europe. Daniela Zackova: served as a member of advisory board for Novartis, served on a speaker’s bureau for Novartis, Pfizer and Angelini, served as a consultant for Novartis and Angelini, and received travel grants from Novartis, Pfizer and Angelini. Andreas Hochhaus: Honoraria and research funding (Novartis, Incyte); research funding (Bristol Myers Squibb, Pfizer, MSD). Susanne Saussele: Honoraria: Novartis, Pfizer, Roche, Incyte. Research support, Novartis, BMS, Incyte.
